Evidence map›Paper›PMID 32895491›Full record

Trial reportBone marrow transplantation2021

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.

Natasha Kekre, Haesook T Kim, Julia Hofer, Vincent T Ho, John Koreth, Philippe Armand, Sarah Nikiforow, Mahasweta Gooptu, Rizwan Romee, Edwin P Alyea and 8 more

Erratum issuedAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. The Pathophysiology and Treatment of Graft-Frontiers in immunology · 2021
    Review
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Natasha KekreDivision of Hematology, The Ottawa Hospital, Ottawa, ON, Canada.
Haesook T KimDepartment of Data Sciences, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA.
Julia HoferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6098-1603
Sarah NikiforowDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mahasweta GooptuDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Rizwan RomeeDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Prashant NageshwarDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Brett GlotzbeckerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Areej El-JawahriBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7994-8974
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4627-1714
Yi-Bin ChenBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9554-1058
Corey CutlerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. corey_cutler@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-8728-4314
Harvard University · USMassachusetts General Hospital · USDana-Farber Cancer Institute · USOttawa Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The α4ß7 integrin is upregulated on naive and memory T cell subsets in patients who subsequently develop gastrointestinal (GI) acute GVHD. Natalizumab (Tysabri

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAcute DiseaseAdrenal Cortex HormonesAdultAgedFemaleGastrointestinal TractHumansMaleMiddle AgedNatalizumabTransplantation ConditioningAdrenal Cortex HormonesNatalizumab

Identifiers

PMID32895491
OpenAlexW3083382067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.